目的 分析遼寧省腫瘤醫(yī)院抗腫瘤輔助用藥的應(yīng)用情況，為臨床合理用藥提供參考。方法 對(duì)2014-2016年遼寧省腫瘤醫(yī)院抗腫瘤輔助用藥的銷售金額、用藥頻度（DDDs）、限定日費(fèi)用（DDC）等進(jìn)行統(tǒng)計(jì)分析。結(jié)果 2014-2016年抗腫瘤輔助用藥的銷售金額逐年增加；中成藥銷售金額連續(xù)3年均排在第1位；康艾注射液的銷售金額逐年增加，排序均居第1位；注射用泮托拉唑鈉的DDDs始終排在第1位；各個(gè)藥品的DDC值相對(duì)較穩(wěn)定，DDC較高的有康艾注射液、舒肝寧注射液和注射用核糖核酸Ⅱ。結(jié)論 2014-2016年遼寧省腫瘤醫(yī)院抗腫瘤輔助用藥的應(yīng)用總體上合理，但仍需加強(qiáng)監(jiān)督管理，規(guī)范輔助用藥使用行為。

Objective To analyze the usage of anti-tumor adjuvant drugs, and to provide reference for rational use of anti-tumor adjuvant drugs. Methods Consumption sum, defined daily doses (DDDs), and defined daily cost (DDC) of anti-tumor adjuvant drugs in Liaoning Cancer Hospital and Institute from 2014 to 2016 were analyzed statistically. Results From 2014 to 2016, the total consumption sums of anti-tumor adjuvant drugs were increasing year by year. Consumption sums of Chinese traditional patent medicine ranked the first for three years. The sales amount of Kang'ai Injection increased year by year, and always ranked the first. DDDs of Pantoprazole for injection ranked the first for three years. DDC values of anti-tumor adjuvant drugs were relatively stable. DDC of Kang'ai Injection, Shuganning Injection, and Ribonucleic acid Ⅱ for injection were higher. Conclusion The application of anti-tumor adjuvant drugs in Liaoning Cancer Hospital and Institute from 2014 to 2016 is rational on the whole, meanwhile, supervision should be strengthened to standardize medication behavior.